KRBP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KRBP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Kiromic BioPharma's Total Liabilities for the quarter that ended in Mar. 2024 was $19.84 Mil. Kiromic BioPharma's Total Assets for the quarter that ended in Mar. 2024 was $12.63 Mil. Therefore, Kiromic BioPharma's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 was 1.57.
The historical data trend for Kiromic BioPharma's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiromic BioPharma Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Liabilities-to-Assets | Get a 7-Day Free Trial | 0.25 | 0.11 | 0.11 | 1.48 | 1.75 |
Kiromic BioPharma Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Liabilities-to-Assets | Get a 7-Day Free Trial | 1.62 | 1.46 | 1.32 | 1.75 | 1.57 |
For the Biotechnology subindustry, Kiromic BioPharma's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Kiromic BioPharma's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Kiromic BioPharma's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Kiromic BioPharma's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
Liabilities-to-Assets (A: Dec. 2023 ) | = | Total Liabilities | / | Total Assets |
= | 21.29 | / | 12.169 | |
= | 1.75 |
Kiromic BioPharma's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 is calculated as
Liabilities-to-Assets (Q: Mar. 2024 ) | = | Total Liabilities | / | Total Assets |
= | 19.84 | / | 12.628 | |
= | 1.57 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiromic BioPharma (OTCPK:KRBP) Liabilities-to-Assets Explanation
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Thank you for viewing the detailed overview of Kiromic BioPharma's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Brian Hungerford | officer: CFO | 7707 FANNIN, SUITE 140, HOUSTON TX 77054 |
Pamela Misajon | director | 7707 FANNIN ST, SUITE 140, HOUSTON TX 77054 |
Michael Catlin | director | 7707 FANNIN ST, SUITE 140, HOUSTON TX 77054 |
Karen Reeves | director | 7707 FANNIN, SUITE 140, HOUSTON TX 77054 |
Francis X Tirelli | director | 7707 FANNIN, SUITE 140, HOUSTON TX 77054 |
Daniel Grant Clark | officer: Interim CFO | 7707 FANNIN, SUITE 140, HOUSTON TX 77054 |
Internati Maurizio Chiriva | director, officer: Chairman, CEO, and President | 7707 FANNIN, SUITE 140, HOUSTON TX 77054 |
Michael Charles Ryan | officer: Chief Technology Officer | 7707 FANNIN, SUITE 140, HOUSTON TX 77054 |
Ignacio Nunez | officer: See Remarks | 7707 FANNIN, SUITE 140, HOUSTON TX 77054 |
Jerry A. Schneider | director | ONE VISION DRIVE, NATICK MA 01760 |
Michael Nagel | director | C/O VASCULAR SOLUTIONS INC, 6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369 |
Pietro Bersani | director | C/O FUEL SYSTEMS SOLUTIONS, INC., 780 THIRD AVE. 25TH FLOOR, NEW YORK NY 10017 |
Scott Dahlbeck | officer: Chief Medical Officer | 7707 FANNIN, SUITE 140, HOUSTON TX 77054 |
Americo Cicchetti | director | 7707 FANNIN, SUITE 140, HOUSTON TX 77054 |
Gianluca Rotino | director, officer: CSIO | 7707 FANNIN, SUITE 140, HOUSTON TX 77054 |
From GuruFocus
By Ds*** Ds*** • 08-29-2022
By PRNewswire PRNewswire • 08-29-2022
By PRNewswire PRNewswire • 08-24-2022
By PurpleRose PurpleRose • 08-22-2022
By Business Wire Business Wire • 08-22-2022
By Business Wire Business Wire • 10-27-2022
By PRNewswire PRNewswire • 09-01-2022
By Business Wire Business Wire • 02-28-2023
By PRNewswire PRNewswire • 09-01-2022
By PRNewswire PRNewswire • 09-02-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.